期刊文献+

二肽基肽酶4抑制剂与心血管疾病相关性的研究进展 被引量:2

Research progress of dipeptidyl peptidase 4 inhibitor and cardiovascular disease
下载PDF
导出
摘要 目前新型口服降糖药二肽基肽酶4 (DPP4)抑制剂以其在肠促胰岛素分解代谢血糖中的作用而被用于糖尿病治疗中.糖尿病是一种以高血糖为特征的代谢性疾病,它的发病机制与遗传因素和免疫功能紊乱等因素有关[1].2型糖尿病不仅与胰岛素抵抗相关,使患者的胰岛素信号受损,还会增加相关心血管疾病(CVD)风险.二肽基肽酶4不仅能控制血糖,改善胰岛素代谢信号和胰岛素抵抗,还具有潜在的心血管保护作用.
出处 《中国心血管病研究》 CAS 2015年第2期121-125,共5页 Chinese Journal of Cardiovascular Research
关键词 二肽基肽酶4抑制剂 2型糖尿病 心血管疾病 Dipeptidyl peptidase 4 inhibitor Type 2 diabet Cardiovascular disease
  • 相关文献

参考文献1

二级参考文献17

  • 1Cushman WC,Evans GW,Byington RP,et al.ACCORD Study Group.Effects of intensive blood-pressure control in type 2 diabetes mellitus.N Engl J Med,2010,362:1575-1585.
  • 2Bavry AA,Anderson RD,Gong Y,et al.Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease:findings from the INternational VErapamil-SR/Trandolapril STudy.Hypertension,2010,55:48-53.
  • 3Chan JC,Malik V,Jia W,et al.Diabetes in Asia:epidemiology,risk factors,and pathophysiology.JAMA,2009,301:2129-2140.
  • 4Yang W,Lu J,Weng J,et al.China national diabetes and metabolic disorders study group.Prevalence of diabetes among men and women in China.N Engl J Med,2010,362:1090-1101.
  • 5Holman RR,Haffner SM,McMurray JJ,et al.NAVIGATOR study group,effect of nateglinide on the incidence of diabetes and cardiovascular events.N Engl J Med,2010,362:1463-1476.
  • 6McMurray JJ,Holman RR,Haffner SM,et al.NAVIGATOR study greup,effect of valsartan on the incidence of diabetes and cardiovascular events.N Engl J Med,2010,362:1477-1490.
  • 7Nathan DM.Navigating the choices for diabetes prevention.N Engl J Med,2010,362:1533-1535.
  • 8Calles-Escand(o)n J,Lovato LC,Simons-Morton DG,et al.Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics:the ACCORD trial.Diabetes Care,2010,33:721-727.
  • 9Riddle MC,Ambresius WT,Brillon DJ,et al.Action to Central Cardiovascular Risk in Diabetes Investigators.Epidemiologlc relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.Diabetes Care,2010,33:983-990.
  • 10Bonds DE,Miller ME,Bergenstal RM,et al.The association between symptomatic,severe hypoglycaemia and mortality in type 2 diabetes:retrospective epidemiological analysis of the ACCORD study.BMJ,2010,340:b4909.

共引文献5

同被引文献18

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部